Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View

Dr. Christin Collins

Breast Surgical Onc · MetroHealth

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    PBDr. Peter Beitsch

    Dr. Peter Beitsch

    Surgery · Breast Surgical Oncology
    Dallas Surgical Group
    peterbeitsch

    Research

    Tyrer-Cuzick Lifetime Risk Is Not Associated With Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma

    2026

    Via The Breast Journal

    Research

    Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King

    2025

    Via International Journal of Molecular Sciences

    Research

    Utilization of Cancer Screening, Prevention, and Treatment in Women With Variants of Uncertain Significance in Breast Cancer Susceptibility Genes

    2025

    Via Journal of the National Comprehensive Cancer Network

    Research

    Authors' Reply to the Letter to the Editor by Stimac and Bayley: Utilization of Cancer Screening, Prevention, and Treatment in Women With Variants of Uncertain Significance in Breast Cancer Susceptibility Genes

    2025

    Via Journal of the National Comprehensive Cancer Network

    Research

    Cascade Testing for Hereditary Cancer: Comprehensive Multigene Panels Identify Unexpected Actionable Findings in Relatives

    2024

    Via Journal of the National Cancer Institute

    Research

    Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer

    2024

    Via Journal of Clinical Oncology

    Research

    Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

    2022

    Via Annals of Surgical Oncology

    Research

    Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

    2022

    Via JCO Precision Oncology

    Research

    Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial

    2022

    Via JAMA Surgery

    Research

    Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial

    2022

    Via JAMA Surgery

    Research

    Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy

    2022

    Via JCO Precision Oncology

    Research

    Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer

    2022

    Via JAMA Network Open

    Research

    Combined 70- and 80-Gene Signatures Identify Tumors With Genomically Luminal Biology Responsive to Neoadjuvant Endocrine Therapy and Are Prognostic of 5-Year Outcome in Early-Stage Breast Cancer

    2022

    Via Surgical Oncology

    Research

    Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial

    2021

    Via Annals of Surgery

    Research

    Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction

    2021

    Via JCO Precision Oncology